These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 20490982)

  • 1. Heterogeneity of the tumor vasculature.
    Nagy JA; Chang SH; Shih SC; Dvorak AM; Dvorak HF
    Semin Thromb Hemost; 2010 Apr; 36(3):321-31. PubMed ID: 20490982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets.
    Nagy JA; Dvorak HF
    Clin Exp Metastasis; 2012 Oct; 29(7):657-62. PubMed ID: 22692562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor Stroma, Tumor Blood Vessels, and Antiangiogenesis Therapy.
    Dvorak HF
    Cancer J; 2015; 21(4):237-43. PubMed ID: 26222073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-VEGF/VEGFR therapy for cancer: reassessing the target.
    Sitohy B; Nagy JA; Dvorak HF
    Cancer Res; 2012 Apr; 72(8):1909-14. PubMed ID: 22508695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy.
    Sitohy B; Nagy JA; Jaminet SC; Dvorak HF
    Cancer Res; 2011 Nov; 71(22):7021-8. PubMed ID: 21937680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
    Pradeep CR; Sunila ES; Kuttan G
    Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revisiting tumor angiogenesis: vessel co-option, vessel remodeling, and cancer cell-derived vasculature formation.
    Qian CN; Tan MH; Yang JP; Cao Y
    Chin J Cancer; 2016 Jan; 35():10. PubMed ID: 26747273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation.
    Chang SH; Kanasaki K; Gocheva V; Blum G; Harper J; Moses MA; Shih SC; Nagy JA; Joyce J; Bogyo M; Kalluri R; Dvorak HF
    Cancer Res; 2009 May; 69(10):4537-44. PubMed ID: 19435903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Permeability properties of tumor surrogate blood vessels induced by VEGF-A.
    Nagy JA; Feng D; Vasile E; Wong WH; Shih SC; Dvorak AM; Dvorak HF
    Lab Invest; 2006 Aug; 86(8):767-80. PubMed ID: 16732297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chapter 3. The adenoviral vector angiogenesis/lymphangiogenesis assay.
    Nagy JA; Shih SC; Wong WH; Dvorak AM; Dvorak HF
    Methods Enzymol; 2008; 444():43-64. PubMed ID: 19007660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
    Jain RK
    Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular endothelial growth factor as a therapeutic target in cancer.
    Bergsland EK
    Am J Health Syst Pharm; 2004 Nov; 61(21 Suppl 5):S4-11. PubMed ID: 15552621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer strategies involving the vasculature.
    Heath VL; Bicknell R
    Nat Rev Clin Oncol; 2009 Jul; 6(7):395-404. PubMed ID: 19424102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VEGF-A and the induction of pathological angiogenesis.
    Nagy JA; Dvorak AM; Dvorak HF
    Annu Rev Pathol; 2007; 2():251-75. PubMed ID: 18039100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tumor angiogenesis: new approaches to cancer therapy].
    Marmé D
    Onkologie; 2001 Feb; 24 Suppl 1():1-5. PubMed ID: 11441305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery.
    Sundberg C; Nagy JA; Brown LF; Feng D; Eckelhoefer IA; Manseau EJ; Dvorak AM; Dvorak HF
    Am J Pathol; 2001 Mar; 158(3):1145-60. PubMed ID: 11238063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Actions of Anti-Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Drugs on Angiogenic Blood Vessels.
    Sitohy B; Chang S; Sciuto TE; Masse E; Shen M; Kang PM; Jaminet SC; Benjamin LE; Bhatt RS; Dvorak AM; Nagy JA; Dvorak HF
    Am J Pathol; 2017 Oct; 187(10):2337-2347. PubMed ID: 28736316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.
    Shinkaruk S; Bayle M; Laïn G; Déléris G
    Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):95-117. PubMed ID: 12678905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor angiogenesis: causes, consequences, challenges and opportunities.
    Lugano R; Ramachandran M; Dimberg A
    Cell Mol Life Sci; 2020 May; 77(9):1745-1770. PubMed ID: 31690961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.